Earnings Beat: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Yahoo FinanceMay 5 20:10

Agios Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Agios Pharmaceuticals Is Maintained at Neutral by Goldman Sachs

Dow JonesMay 4 00:00

Goldman Sachs: Maintaining the Agios Pharmaceuticals (AGIO.US) rating, adjusted from neutral to neutral, and adjusted the target price from $29.00 to $33.00.

Goldman Sachs: Maintaining the Agios Pharmaceuticals (AGIO.US) rating, adjusted from neutral to neutral, and adjusted the target price from $29.00 to $33.00.

Zhitong FinanceMay 3 23:51

Goldman Sachs Maintains Neutral on Agios Pharmaceuticals, Raises Price Target to $33

Goldman Sachs analyst Salveen Richter maintains Agios Pharmaceuticals (NASDAQ:AGIO) with a Neutral and raises the price target from $29 to $33.

BenzingaMay 3 23:50

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q1 2024 Earnings Call Transcript

Yahoo FinanceMay 3 23:10

Agios to Present at the RBC Capital Markets Global Healthcare Conference on May 14, 2024

CAMBRIDGE, Mass., May 03, 2024 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and PK activation pioneering therapies for rare diseases, today announced that the company

GlobeNewswireMay 3 19:00